Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 157 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Melphalan flufenamide in combination with dexamethasone for treating adult patients with relapsed or refractory multiple myeloma	Dexamethasone (dexamethasone sodium metasulfobenzoate) , Melphalan flufenamide hydrochloride (Ygalo; Mel-flufen; J-1)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2020	View \| Download
Momelotinib for the treatment of symptomatic and anaemic myelofibrosis	Momelotinib	Anaemic myelofibrosis	Haematological Cancer and Lymphomas , Haematology	2022	View \| Download
Mosunetuzumab (subcutaneous injection) for treating relapsed or refractory follicular lymphoma	Mosunetuzumab (BTCT4465A)	Follicular lymphoma	Haematological Cancer and Lymphomas	2024	View \| Download
Mosunetuzumab for relapsed or refractory B-cell follicular lymphoma – third-line and greater	Mosunetuzumab (BTCT4465A)	Follicular lymphoma	Haematological Cancer and Lymphomas	2021	View \| Download
Navitoclax with ruxolitinib for myelofibrosis	Navitoclax (ABT 263, ABT-263) , Ruxolitinib (Jakavi; INCB018424; CTP-543; ruxolitinib phosphate)	Myelofibrosis	Haematological Cancer and Lymphomas	2022	View \| Download
Obecabtagene autoleucel for treating refractory or relapsed B cell acute lymphoblastic leukaemia	Obecabtagene autoleucel	Acute lymphoblastic leukaemia (ALL)	Haematological Cancer and Lymphomas	2023	View \| Download
Parsaclisib for marginal zone lymphoma – relapsed or refractory	Parsaclisib (INCB050465)	Marginal zone lymphoma (MZL)	Haematological Cancer and Lymphomas	2021	View \| Download
Pembrolizumab (Keytruda) for relapsed/refractory classical Hodgkin lymphoma	Pembrolizumab (Keytruda; MK-3475)	Hodgkin lymphoma	Haematological Cancer and Lymphomas	2018	View \| Download
Pembrolizumab for treatment of solid tumours – second line	Pembrolizumab (Keytruda; MK-3475)	Solid tumours	Haematological Cancer and Lymphomas , Oncology	2021	View \| Download
Pemigatinib for treating myeloproliferative neoplasms with FGFR1 rearrangement	Pemigatinib (INCB054828)	Myeloproliferative Neoplasms	Haematological Cancer and Lymphomas	2022	View \| Download